MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study ...
MacroGenics presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) at ESMO, showing encouraging antitumor activity with a 6-month landmark rPFS rate and ORR. Patients remained on vobra duo through a median of 6 doses, extending treatment duration compared to Phase 1. The company expects mature median rPFS data by early 2025 and will host an investor call on September 16, 2024.
Reference News
MacroGenics presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) at ESMO, showing encouraging antitumor activity with a 6-month landmark rPFS rate and ORR. Patients remained on vobra duo through a median of 6 doses, extending treatment duration compared to Phase 1. The company expects mature median rPFS data by early 2025 and will host an investor call on September 16, 2024.